> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# eMed plans U.S. launch of at-home screening for the condition formerly known as PCOS
- URL: https://www.healthdatacon.io/articles/emed-pmos-at-home-screening-glp1-hlth-2026/
- Published: 2026-11-16T19:25:00.000Z
- Updated: 2026-11-18T04:48:13.000Z
- Description: eMed plans to mail screening kits and connect patients with a clinician. The interview also examined what the company’s UK GLP-1 study shows and how employers may cover the drug.
- Author: HDM Staff
- Tags: Patient Care, Americas, HLTH

eMed plans to offer U.S. patients at-home screening for polyendocrine metabolic ovarian syndrome by the end of 2026, CEO Linda Yaccarino said during a Nov. 16 [Main Stage interview](https://hlth.com/event-recordings/hlth26/sessions/glp-1s-womens-healths-biggest-untapped-opportunity?ref=healthdatacon.io) in Las Vegas. The company plans to mail a test kit, guide users through the process remotely and connect them with a clinician to review the result. Its sister company SheMed already offers screening in the United Kingdom. Yaccarino gave a U.S. target for the rollout and did not disclose a price.

The interview turned on what happens after that conversation. Business Insider health correspondent Hilary Brueck asked whether someone who screens positive for the condition, previously known as polycystic ovary syndrome or PCOS, could get a GLP-1 prescription without otherwise meeting eligibility criteria. “We don’t prescribe off-label,” Yaccarino said. She described access to a screening kit and a clinician, without outlining a separate prescription pathway based on the screening result alone.

## A screening result can start a clinical conversation

![Linda Yaccarino and Hilary Brueck seated onstage.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-glp-12742280054.jpg)

Linda Yaccarino, left, speaks with Hilary Brueck at HLTH USA. Photo credit: HLTH USA 2026.

Yaccarino said the company would adapt the setup it uses for its general eMed kits. A person would receive a kit specific to the condition and have remote guidance while using it. She discussed biomarker testing and other measurements, including waist circumference, and said a clinician could explain whether the findings suggested PMOS. The U.K. offering combines a questionnaire with blood collected at home. The company did not present U.S. results on how many positive screens are subsequently confirmed by a clinician.

Brueck’s question points to a distinction that matters when someone orders a test. A result that suggests PMOS can give a person and a clinician a reason to investigate. The assessment must also consider the person’s symptoms and other possible explanations. A medication decision comes later and depends on the purpose of treatment and the person's eligibility. The [international clinical guideline](https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polyendocrine-metabolic-ovarian-syndrome-2023/?ref=healthdatacon.io) says GLP-1 medicines may be considered for managing higher weight in adults with PMOS under general population guidance. It does not turn the screening result into an indication for a drug.

Yaccarino said the project grew in part from the experience of SheMed co-founder Olivia Ferro, who she said went through years of seeking an explanation for her symptoms. She framed the mailing program as a way to start an assessment sooner. The strength of that model depends on what it does after delivering the result. Someone with a result suggesting PMOS needs a way to discuss what it means and what assessment may follow. Someone whose symptoms continue after a result that does not indicate the condition still needs a way to raise those concerns.

## What the UK experience says about follow-up

![Linda Yaccarino gestures while speaking.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-glp-12742280065.jpg)

eMed CEO Linda Yaccarino discusses the company’s approach to GLP-1 care. Photo credit: HLTH USA 2026.

Brueck also asked about an [observational study published in Nature Medicine](https://www.nature.com/articles/s41591-026-04687-x?ref=healthdatacon.io), in which 8,127 women began GLP-1 therapy through SheMed’s U.K. program. Nearly all received tirzepatide. The study reported that 91.4% remained on treatment at six months and that mean weight fell by 16.1 kilograms, or about 35 pounds. The program required biochemical monitoring and weekly video-supported follow-up, and clinicians guided changes to dose. Those details describe what the service delivered alongside the prescription.

“You check in with us every week,” Yaccarino said, describing how patients report progress and how the company can hold a dose steady if a patient continues to progress. That makes follow-up an operating requirement. A provider has to review the information that comes in, decide when a concern needs a response and decide who follows up between scheduled contacts. An enrollment figure on its own says little about the staffing and clinical work behind that process.

The study describes a particular population that selected and paid for a service in one market. It had no comparison group and followed participants for six months. It cannot establish how much of the change was due to the drug, how much was due to the follow-up model or whether the same results would occur in an employer-sponsored U.S. program. It also studied people starting medication. It supplies no estimate of the accuracy of the proposed U.S. screening kit or how often it will lead to a confirmed PMOS diagnosis.

The authors reported that 62.7% of participants experienced at least one side effect and that they found no serious adverse events related to treatment. Those findings can coexist with high retention. They are also a reason to ask what follow-up actually provides. When symptoms are common, a remote program’s ability to assess a concern or connect a patient with a clinician matters independently of the proportion of patients still taking a medicine when the study ends.

![Hilary Brueck holds a Business Insider card while moderating.](https://storage.ghost.io/c/91/db/91db0927-dd9a-4578-9944-921da70f6885/content/images/2026/11/hlth-glp-12742280070.jpg)

Business Insider health correspondent Hilary Brueck moderates the interview. Photo credit: HLTH USA 2026.

## The employer can cover the service and the drug differently

The subject shifted from finding a condition to paying for treatment when Brueck asked about open enrollment. She described employers that might pay for the eMed subscription while employees still pay for medication. Yaccarino said agreements vary by company. She described negotiating around what an employer is willing to cover and argued that lower prices for the drugs would make it easier for employers to offer the benefit. Those were her expectations about how coverage could change.

For an employee, the distinction can show up in two separate bills. A benefit may pay for an assessment, check-ins and access to a clinician. What the employee pays for the prescription still depends on how the drug is covered. The interview gave no single monthly price or universal employer policy. The terms of a specific plan determine whether the member has a copayment, must pay a larger share or has no drug benefit under that arrangement.

Yaccarino argued that employers should consider the cost of the medication alongside what they expect a care program to deliver. The evidence reviewed earlier in the session helps explain which questions an employer could ask. Retention tells a buyer how many participants stayed in a program during the study. It does not establish how a different group of employees will use a benefit or what the benefit will cost their employer over time.

The U.S. rollout Yaccarino described would change where a person can start asking whether PMOS explains their symptoms. The study discussed onstage offers an example of the follow-up SheMed has provided to a separate group already receiving treatment. The two together show why buyers and patients need to ask what is included at each step. A mailed kit, a clinical assessment, a prescription and the amount someone pays each month are different parts of the experience. Monday’s announcement set a target for the first of those steps.